// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Comparison of pulmonary rehabilitation outcomes for different conditions and disease severities

Callum Masey - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Depression

N/A

Pulmonary rehabilitation in patients with group 3 pulmonary hypertension: evaluation of clinical outcomes, adherence and safety

Laura Moth - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary arterial hypertension

N/A

COPD and palliative care: a collaborative model to improve quality of life and reduce readmissions

Kay Roy - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

The responsiveness of skeletal muscle mRNAs to aerobic exercise training is not blunted in COPD

Lorna Latimer - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

What influences the survival advantage following Pulmonary Rehabilitation in patients with COPD?

Rachael A. Evans - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Quality of spirometry and diffusion of the lung (DLCO) data in patients with systemic sclerosis

Carl Mottram - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Hypoxic challenge test and sleep study results in chronic lung disease patients

Mollie Riley - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Validation of nitric oxide transfer factor predicted equations

Matthew Austin - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nitric oxide

Predicting maximal heart rate (HRMax) in patients on ß-blockers from a cardiopulmonary exercise test (CPET)

Adrian Hugh Kendrick - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cardio-Pulmonary function in adolescents with Pectus Excavatum and the impact of surgical intervention

Paul Burns - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Lung function in relation to emphysema development in alpha-1 antitrypsin deficiency

James Stockley - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Alpha-1 antitrypsin (A1AT) deficiency

Alpha 1-Antitrypsin

On the temporal characterisation of novel capnometric indices for personalised monitoring and treatment optimisation of COPD

John Altrip - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Differences in forced oscillation between mouthpiece and mask

Malak Alshlowi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A survey of rest period between spirometry efforts before and after bronchodilator administration

Bethany Coupland - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The prevalence of patients with normal post-bronchodilator spirometry that fulfil the criteria for GOLD mild COPD using ECCS predicted equations

Sara Mcarthur - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Salbutamol

Health related quality of life in patients with dysfunctional breathing referred to a cardiopulmonary exercise testing service

Julia Rogers - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comparison of small airways disease measures between frequent and infrequent COPD exacerbators

Kerry Gove - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

What is sufficient duration for a paediatric respiratory sleep study in neuromuscular disorders?

Aidan Laverty - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sleep apnoea

N/A

Reproducibility of crackle counts in Bronchiectasis patients

Angela Key - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Within session variability of FEV1 and FVC pre- and post-bronchodilation

Bethany Coupland - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Copyright © 2026. QuantiNova All rights reserved